Skip to main content

Table 1 Demographics and echocardiographic findings of patient cohort

From: Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms

Total number of CYC treated patients, n 10
Male sex 70%
Median Age at Diagnosis of KD (range) 2 years (4 months – 5 years)
Race
 • White • 4
 • Asian • 2
 • Hispanic • 3
 • Not available • 1
Complete KD criteria 50%
Median Day of Illness at 1st IVIG (range) 7 (4–10)
Median Day of Illness at CYCa (range) 22.5 (10–36)
Two doses of CYC 30%
Adjunctive Therapies before CYC
 • Glucocorticoids • 100%
 • Infliximab • 40%
 • Cyclosporine A • 20%
 • Anakinra • 10%
Median Baseline LADb Z score (range) 3.8 (0.68–13.4)
Median Baseline RCAc Z score (range) 2.1 (0.1–12.16)
Median LAD Z Max during admission (range)d 15.7 (4.7–29.6)
Median RCA Z Max during admission (range) d 11.8 (2.0–21.06)
Number of patients with bilateral aneurysms (n, %) 9 (90%)
Number of patients with giant aneurysms (n, %) 8 (80%)
  1. aCyclophosphamide bLeft Anterior Descending Artery; cRight Coronary Artery
  2. dZ max: largest measurement of LAD or RCA, at any point of the course
\